A shift in consumer and provider preferences could hurt revenues for drug manufacturers that don't speed efforts to demonstrate the clinical and economic benefits of their products, according to a new PricewaterhouseCoopers survey.
PwC, London, U.K., published this finding in a survey that explores how well health insurers and pharmaceutical companies work together using information about drug effectiveness in the care of patients. The phone survey of executives at 100 different health insurers uncovered the following:
• To be considered for drug formulary placement, 82% of health plans say a drug manufacturer must demonstrate a clear clinical benefit compared with current branded and generic treatments, and 78% demand clear proof of cost savings.